Michael Christman, PhD, President and CEO.
On “Disease in a Dish” stem cell research.
“Screening drug candidates in a stem cell model will likely result in effective drugs getting into the market faster, since testing in the diseased environment is proven prior to the clinical trial. Significantly, this technology has the potential to offer medicines that are better targeted for individual patients. It also promises to reduce the cost burden of research and development, and in turn, the cost to patients for their prescription drugs.”
Michael Christman, PhD, President and CEO.
On the Coriell Personalized Medicine Collaborative® and partnering with Ohio State Medical Center.
“By providing personal genetic risk data directly to both physicians and their patients, we have a unique opportunity to examine how personalized medicine can be used in the clinic. This is an important step toward effectively integrating genome information into routine medical care.”
Michael Christman, PhD, President and CEO.
On the induced pluripotent stem (iPS) cell laboratory at Coriell.
“This is the perfect opportunity to incorporate a revolutionary technology into the study of rare human disorders with the hope of furthering researchers’ understanding of disease development. We see the introduction of induced pluripotent stem (iPS) cells into Coriell’s collections as critical because of their vast potential for pre-clinical drug trials, therapeutic use, and regenerative medicine.”
Michael Christman, PhD, President and CEO.
On pharmacogenomics (PGx).
“If you have a gene variation that influences how you metabolize a blood thinner, and your physician prescribes dosing instructions accordingly, the practice of medicine is now safer, well-timed, accurate, and cost-effective for you and our healthcare system.”
Michael Christman, PhD, President and CEO.
On personalized medicine.
“Personalized medicine will help physicians identify disease risks sooner and make the best prescribing decisions, resulting in safer and more accurate care for their patients.”
Scott Megill, Chief Information Officer.
On the IT infrastructure that supports the Coriell Personalized Medicine Collaborative® research study.
“When CPMC participants log into the portal, their authentication information and anything that’s personally identifying to the participants is kept in a separate database from the actual genetic information and risk reports. Participants can rest assured that their private data is protected.”
Erynn Gordon, MS, CGC, Director, Genetic Counseling.
On the role of genetic counseling.
"The Coriell Personalized Medicine Collaborative® research study is unique in several ways. One such aspect is the prominent role of genetic counseling in the study. We believe that participants should receive a holistic understanding of their risk results. We also recognize the importance of educating physicians and patients for a near future when they will have access to the incredible amount of genome information available.”
Joseph L. Mintzer, Executive Vice President and COO.
On biobanking.
“Biobanks play a quiet, but crucial role in biomedical research. By integrating large numbers of biospecimens with strong clinical information, we have created a resource that serves both the scientific community and the health of the public at large.”
Courtney Kronenthal, PhD, Director, Communications and Development
On the importance of private philanthropy to Coriell.
“Coriell is a fortunate recipient of several NIH awards that essentially support the renowned Coriell Biobank. On the other hand, the power of private philanthropy in independent medical research is often understated. The generosity of Coriell’s donors has launched several of our cutting-edge research programs, including the Coriell Personalized Medicine Collaborative® research study.”
